Bharat Biotech
-

The big news: Two coronavirus vaccines cleared for emergency use in India, and 9 other top stories
Scroll Staff
-

Covid-19: Serum vaccine to be used in first phase, Bharat Biotech shot back-up, says AIIMS director
Scroll Staff
-

Coronavirus: Serum Institute, Bharat Biotech vaccines 110% safe, says DCGI after emergency approval
Scroll Staff
-

Coronavirus: Congress questions Covaxin’s approval before completing phase-3 trials
Scroll Staff
-

Every Indian proud that vaccines made in India have been given urgent-use approval, says PM Modi
Scroll Staff
-

Coronavirus: India approves vaccines by Serum Institute, Bharat Biotech for restricted emergency use
Scroll Staff
-

The big news: Expert panel clears Covaxin, Covishield for emergency use, and nine other top stories
Scroll Staff
-

Covid-19: India registers over 20,000 new cases, Centre’s panel to decide on vaccine approval
Scroll Staff
-

Covaxin has drawn global attention, says ICMR
Scroll Staff
-

Coronavirus: Antibodies generated by Covaxin may persist for 6-12 months, says Bharat Biotech
Scroll Staff
-

Covaxin induces strong immune response, no serious adverse effects in phase 1 trial: Bharat Biotech
Scroll Staff
-

‘Fake news’: Emergency use approval of Serum Institute, Biotech vaccines not rejected, says Centre
Scroll Staff
-

Covid vaccine: Bharat Biotech, Serum Institute have applied for emergency use, confirms Centre
Scroll Staff
-

Covaxin efficacy determined 14 days post second dose, says Bharat Biotech as Anil Vij tests positive
Scroll Staff
-

Coronavirus vaccine: PM Modi visits Serum Institute in Pune, completes three-city tour
Scroll Staff
-

Coronavirus: PM Modi to visit three vaccine development plants on Saturday to review work
Scroll Staff
-

Coronavirus: Covaxin will be at least 60% effective, says Bharat Biotech
Scroll Staff
-

Coronavirus: Bharat Biotech begins phase 3 trials of Covaxin in India
Scroll Staff
-

Coronavirus: Centre to increase bed count, double tests conducted daily in Delhi
Scroll Staff
-

Coronavirus: Covaxin could be available as early as February, says ICMR scientist
Scroll Staff